Trial record 1 of 2 for:    epidermolysis bullosa acquisita
Previous Study | Return to List | Next Study

Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita

This study has been completed.
Sponsor:
Collaborator:
Northwestern University
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00004359
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: January 2000

October 18, 1999
June 23, 2005
February 1996
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00004359 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita
Not Provided

OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita.

II. Investigate the effect of ECP on lymphocyte activity.

PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days.

Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.

Interventional
Phase 2
Primary Purpose: Treatment
Epidermolysis Bullosa Acquisita
Drug: methoxsalen
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
Not Provided
Not Provided
  • Active epidermolysis bullosa acquisita
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00004359
199/11928, NU-511
Not Provided
Not Provided
National Center for Research Resources (NCRR)
Northwestern University
Study Chair: Kenneth B. Gordon Northwestern University
Office of Rare Diseases (ORD)
January 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP